Research Article| Volume 58, ISSUE 2, P190-193, February 2020

Clinical evaluation of botulinum toxin A in the management of temporomandibular myofascial pain

Published:December 15, 2019DOI:


      We did a clinical service evaluation of patient-reported outcomes for pain and change in interincisal distance in patients treated with botulinum toxin A (BTX-A) for temporomandibular myofascial pain at nurse-led clinics. We retrospectively reviewed the clinical records of 100 patients and the prescribing patterns of two OMFS consultants. The mean starting pain score of 7.54 out of 10 was reduced by a mean (SD) of 2.48 (2.1) points after the intervention (p < 0.001). The most common prescription was for 100 units (n = 59 prescriptions). The change in the mean pain scores did not differ significantly whether 100 or 200 units were prescribed (p = 0.19). Interincisal distance increased by a mean (SD) of 0.5 (5.24) mm after treatment with BTX-A, which was not significant (p = 0.35). In most cases the treatment helped to manage and reduce the symptoms of temporomandibular myofascial pain. Considerable improvement in interincisal distance as a result of this treatment alone, however, is unlikely, but it may have a role in a multifaceted approach, particularly when other conservative methods have failed. The use of a pro forma may allow for more consistent record keeping and the detailed assessment of patient-reported pain scores in the weeks and months after treatment. Development of an electronic patient-reported outcome (ePRO) tool may facilitate this further.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to British Journal of Oral and Maxillofacial Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • The International Centre for Allied Health Evidence
        Systematic review of literature. The effectiveness of injection of botulinum neurotoxin for myofascial pain as a form of interventional pain management: technical report. Prepared for the Accident Compensation Corporation.
        (New Zealand. Available from URL: (last accessed 6 November 2019))2017
        • Khawaja S.N.
        • Crow H.
        • Holmlund T.
        • et al.
        Botulinum toxin type A for the management of masticatory muscle pain in temporomandibular disorders: a systematic review.
        J Dent Health Oral Disord Ther. 2017; 7: 00266
        • Ernberg M.
        • Hedenberg-Magnusson B.
        • List T.
        • et al.
        Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study.
        Pain. 2011; 152: 1988-1996
        • Chen Y.W.
        • Chiu Y.W.
        • Chen C.Y.
        • et al.
        Botulinum toxin therapy for temporomandibular joint disorders: a systematic review of randomized controlled trials.
        Int J Oral Maxillofac Surg. 2015; 44: 1018-1026
        • Sunil Dutt C.
        • Ramnani P.
        • Thakur D.
        • et al.
        Botulinum toxin in the treatment of muscle specific oro-facial pain: a literature review.
        J Maxillofac Oral Surg. 2015; 14: 171-175
        • South East London Area Prescribing Committee Formulary recommendation
        Botulinum toxin type A injection for the treatment of myofascial pain syndrome associated with temporomandibular jaw dysfunction (TMJD) Reference 051.
        (Available from URL: (last accessed 6 November 2019))2016
        • Sidebottom A.J.
        • Patel A.A.
        • Amin J.
        Botulinum injection for the management of myofascial pain in the masticatory muscles. A prospective outcome study.
        Br J Oral Maxillofac Surg. 2013; 51: 199-205
        • Kahn A.
        • Bertin H.
        • Corre P.
        • et al.
        Assessing the effectiveness of botulinum toxin injections into masticatory muscles in the treatment of temporomandibular disorders.
        J Oral Med Oral Surg. 2018; 24: 107-111
        • Gupta A.
        • Aggarwal A.
        • Aggarwal A.
        Effect of botulinum toxin-A in myofascial pain in temporomandibular disorders: a randomized, double-blinded, placebo-controlled study.
        Indian J. Pain. 2016; 30: 166-170
        • Machado E.
        • Machado P.
        • Wandscher V.F.
        • et al.
        A systematic review of different substance injection and dry needling for treatment of temporomandibular myofascial pain.
        Int J Oral Maxillofac Surg. 2018; 47: 1420-1432
        • Naumann M.
        • Carruthers A.
        • Carruthers J.
        • et al.
        Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications.
        Mov Disord. 2010; 25: 2211-2218
        • Coons S.J.
        • Eremenco S.
        • Lundy J.J.
        • et al.
        Capturing patient-reported outcome (PRO) data electronically: the past, present, and promise of ePRO measurement in clinical trials.
        Patient. 2015; 8: 301-309